Incyte Announces First Patient Treated in Phase 3 Clinical Trial Program for Ruxolitinib Cream in Atopic Dermatitis
“Atopic dermatitis can have a serious impact on patients’ overall health
and quality of life and, unfortunately, the long-term use of
prescription topical corticosteroids can lead to significant side
effects, underscoring the medical need for new topical therapies to
treat this chronic skin disease,” said
AD is a common chronic disease characterized by inflammation of the
skin. At least 11 million people in
About TRuE- AD
The TRuE-AD clinical trial program includes two Phase 3 studies (NCT03745638 and NCT03745651) evaluating the safety and efficacy of ruxolitinib cream in patients with atopic dermatitis (AD).
The studies will each enroll approximately 600 patients (age ≥ 12 years) who have been diagnosed with AD for at least two years, who have an Investigator’s Global Assessment (IGA) score of 2 to 3, a Body Surface Area (BSA) involvement (excluding scalp) of 3% to 20% and who are candidates for topical therapy. Participants will be randomized 2:2:1 into one of three treatment arms.
The primary endpoint of the TRuE-AD studies is the proportion of participants achieving an Investigator’s Global Assessment Treatment Success (IGA-TS), defined as an IGA score of 0 (clear) or 1 (almost clear) with at least a 2-point improvement from baseline at Week 8. Key secondary endpoints include: the proportion of patients achieving at least a 75 percent improvement from baseline in the Eczema Area and Severity Index (EASI) score – a measurement of the extent and severity of AD – or EASI75, and the proportion of participants with at least a four-point improvement in the itch numerical rating scale (NRS). The studies will also track the frequency, duration and severity of adverse events associated with the use of ruxolitinib cream.
Forward Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the Company’s ongoing clinical development program for ruxolitinib cream in patients with atopic dermatitis, and the enrollment, design, timing and results of the TRuE-AD clinical trial program, contain predictions, estimates and other forward-looking statements.
These forward-looking statements are based on the Company’s current
expectations and subject to risks and uncertainties that may cause
actual results to differ materially, including unanticipated
developments in and risks related to: unanticipated delays; further
research and development and the results of clinical trials possibly
being unsuccessful or insufficient to meet applicable regulatory
standards or warrant continued development; the ability to enroll
sufficient numbers of subjects in clinical trials; determinations made
+1 302 498 6171
Michael Booth, DPhil
+1 302 498 5914